Asset Details
Do you wish to reserve the book?
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials
Do you wish to request the book?
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials
2024
Overview
INTRODUCTION Adverse effects of monoclonal antibodies against amyloid beta are common, and may affect validity of randomized controlled trials (RCTs) through unblinding of participants. METHODS We used observations from published phase 3 RCTs in Alzheimer's disease to calculate the magnitude of unblinding effects on cognition that would be required to explain observed cognitive benefits in RCTs. RESULTS In trials of lecanemab, aducanumab, and donanemab, incidence of amyloid‐related imaging abnormalities with active treatment ranged from 22% to 44%, the vast majority of which presumably led to unblinding. Effects of unblinding on the Clinical Dementia Rating Sum of Boxes required to fully explain observed drug effects ranged from 1.1 point (95% confidence interval: 0.2–2.0) with aducanumab, to 3.3 points (2.1–4.4) with donanemab and 3.7 points (2.0–5.6) with lecanemab. Infusion‐related reactions were common, with potential unblinding effects particularly for lecanemab. Similar patterns were observed for the Alzheimer's Disease Assessment Scale Cognitive subscale. DISCUSSION Psychological treatment effects due to unblinding may explain a substantial share of observed treatment effects in RCTs.
